Authors
Latest:
Dr Shitara on the 4-Year Outcomes of the CheckMate 649 Trial in GEJ AdenocarcinomaKohei Shitara, MD, discusses first-line nivolumab plus chemotherapy vs chemotherapy alone in gastric cancer, GEJ cancer, or esophageal adenocarcinoma.
Latest:
Dr. Takahashi on Biomarker That Predicts Development of Therapy-Related LeukemiaKoichi Takahashi, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study exploring a potential biomarker for patients likely to develop therapy-related leukemia.
Latest:
HR+/HER2- BC: Selecting a CDK4/6 Inhibitor in the Frontline SettingTaking into account all 3 available CDK4/6 inhibitors in HR+/HER2- breast cancer, experts consider how they’d select frontline therapy in this setting.
Latest:
Dr. Jhaveri on Acquired Resistance to CDK 4/6 Inhibitors in Breast CancerKomal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses acquired resistance to CDK 4/6 inhibitors in breast cancer.
Latest:
Inavolisib or Placebo in Combination With Palbociclib and Fulvestrant in Patients With PIK3CA Mutated, Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer: Phase III INAVO120 Primary AnalysisKomal L. Jhaveri, MD, FACP, presents key data on the addition of inavolisib to palbociclib and fulvestrant vs palbociclib and fulvestrant alone in select patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative, locally advanced, or metastatic breast cancer.
Latest:
Dr. Zakashansky on Maintenance Olaparib in Relapsed BRCA1/2+ Ovarian CancerKonstantin Zakashansky, MD, discusses data with olaparib in advanced, recurrent, platinum-sensitive, BRCA-mutated ovarian cancer.
Latest:
Dr. Leventakos on Remaining Questions After PACIFIC Trial in Lung CancerKonstantinos Leventakos, MD, discusses the impact of the PACIFIC trial on the stage III non–small cell lung cancer treatment, as well as what questions still remain.
Latest:
Dr. Yamoah on Racial Disparities in Prostate CancerKosj Yamoah, MD, a radiation oncologist at Moffit Cancer Center, discusses reasons for understanding the racial disparities in patients with prostate cancer. Yamoah shared this insight during an interview at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.
Latest:
Dr Patel on the Efficacy of Ide-Cel in Patients With High-Risk R/R Multiple MyelomaKrina K. Patel, MD, MSc, discusses the effect of high-risk features on outcomes with ide-cel in triple-class–exposed, relapsed/refractory multiple myeloma.
Latest:
Future Outlooks in the Treatment of R/R DLBCLShared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.
Latest:
Fresh Approaches to RT Improve Outcomes in Retroperitoneal SarcomaEach year, 10% to 15% of patients with soft-tissue carcinomas receive a diagnosis of rare retroperitoneal sarcoma (RPS), an aggressive disease that typically recurs in 26% of cases and has a 47% to 67% five-year overall survival rate. New radiation therapies hold potential to decrease treatment time and provide local control of RPS.
Latest:
Overcoming Barriers to TIL Use in Patients With Solid TumorsClosing out their discussion on TIL therapy, Drs Sarnaik and Komanduri identify existing barriers to TIL use in clinical practice and how the field might optimize patient access to these regimens.
Latest:
Krishna Vanaja Donkena on Using Immune Markers to Predict Survival in Bladder CancerKrishna Vanaja Donkena, PhD, Assistant Professor of Biochemistry and Molecular Biology, Center for Individualized Medicine, Mayo Clinic, discusses using immune and checkpoint markers to predict cancer-specific survival in bladder cancer.
Latest:
FDA Approval Insights: Dostarlimab Plus Chemotherapy in Advanced/Recurrent Endometrial CancerDr Tewari discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.
Latest:
The Future of Clinical Care for Patients With Advanced Endometrial CancerClosing their conversation, Ramez Eskander, MD, and Krishnansu Tewari, MD, share how they envision the future treatment landscape for patients with advanced endometrial cancer.
Latest:
Krista Rubin on Understanding Ipilimumab's ToxicitiesKrista Rubin, from Massachusetts General Hospital Cancer Center, on Understanding Ipilimumab's Toxicities.
Latest:
Future Outlooks in the Treatment of Metastatic Colorectal CancerExperts discuss their vision for the future of colorectal cancer treatment and anticipated advancements in the field.
Latest:
Ganjoo Discusses Treatment Plans, Patient Conversations, and the Role of Nab-Sirolimus in Malignant PEComaDr Ganjoo discusses unmet needs for patients with malignant PEComa, treatment plan considerations, and the use of nab-sirolimus in this disease.
Latest:
Dr. McIntyre on Frontline Eribulin in HER2-Negative MBCKristi McIntyre, MD, from Texas Oncology, discusses the results of a phase II, multicenter, single-arm study that studies eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.
Latest:
Vorasidenib Shows Consistent Efficacy With Manageable Safety in IDH1/2-Mutant Diffuse GliomaUpdated INDIGO data reveal that vorasidenib continues to showcase improved efficacy over placebo in patients with IDH1/2-mutated diffuse glioma.
Latest:
Kristie Howlett on her Patient Hand Wiping TrialKristie Howlett from Sutter Roseville Medical Center on her Patient Hand Wiping Trial
Latest:
Real-World Experience With CAR T Varies From Trials in DLBCLWhen evaluating real-world experience, differences in race/ethnicity and among elderly patients with DLBCL appeared different from those seen in clinical trials, highlighting the need for consideration in these patient populations.
Latest:
Paying It Forward in Oncology: A Journey From Patient to InvestigatorKristin Anderson, PhD, shares her journey from patient to investigator.
